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696excluded that such differences may be due to different methods of
sterol measurements. In contrast to cholesterol, sterol measurements
in different laboratories are not standardized and validated, as has
been shown previously (6). In addition, the data entered in the meta-
analysis were mean or median data rather than individual patient
data. In fact, the authors themselves suggested in their previous
analysis that the next level of evidence should be a meta-analysis of
individual patient data (7).
Our group has previously shown that patients on hemodialysis
are characterized as “high cholesterol absorbers” (8). On longitu-
dinal analysis, higher levels of cholestanol were associated with
increased mortality. Interestingly, in our cohort, higher levels of
cholestanol were associated with lower rather than higher levels of
total cholesterol. These data could explain the ﬁndings in the
SHARP (Study of Heart and Renal Protection) study (9) but are
not in line with the currently reported ﬁndings (1).
The cholesterol absorption rate is dependent on the presence
of bile acids favoring the formation and uptake into micelles
before transport by NPC1L1 from the intestinal lumen into the
enterocyte. The production of bile acids is mainly regulated by
the cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting
enzyme in normal bile acid synthesis. From this point of view, the
polymorphism of CYP7A1 may be more interesting than
the polymorphism of CYP27A1. A marked loss of CYP27A1, as
in cerebrotendineous xanthomatosis, leads to increased produc-
tion of cholestanol. This production is secondary to the marked
induction of CYP7A1 with increased formation of 7a-hydroxy-
4-cholesten-3-one and its further conversion into cholestanol
(10,11). The origin of cholestanol in cerebrotendineous xanthoma-
tosis is thus clearly different from the normal situation.
Finally, in the online ahead of print version of the manuscript,
which differs from the printed version in this regard, Silbernagel et al.
(1) claim that the European Society of Cardiology (ESC)/European
Atherosclerosis Society (EAS) recommend plant sterol–enriched
functional foods. However, the current ESC/EAS guidelines for the
management of dyslipidemias state that “currently there are no data
available indicating that cholesterol lowering through plant sterol
ingestion results in prevention of CVD. Long-term surveillance is
also needed to guarantee the safety of the regular use of phytosterol-
enriched products” (12). In our opinion, both the ESC and the EAS
draw attention to signiﬁcant safety issues, and thus this is not a clear
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The current guidelines for the management of dyslipidemia
endorsed by the European Atherosclerosis Society (EAS) and the
European Society of Cardiology (ESC) do not include a clear
recommendation for the use of plant sterols or stanols as cholesterol-
lowering agents (2). For this reason, we did not make an explicit
statement on this matter (1).
It is correct that plant sterol levels in the LURIC (LUdwigshafen
RIsk and Cardiovascular health) study were lower than those in the
YFS (Young Finns Study) (1). This observation may be accounted
for by several factors (3,4). For example, a healthy diet rich in fruits
and vegetables is associated with high circulating plant sterols (3).
By contrast, old age, high body mass index, type 2 diabetes, and
inﬂammation are associated with low plant sterol concentrations
(3,4). The participants in the LURIC study were markedly older
and had a higher body mass index than the participants in the YFS.
Moreover, the LURIC cohort had a high prevalence of diabetes
and displayed increased markers of inﬂammation. On the other
hand, the participants in the YFS may have maintained a more
healthy diet than a typical patient with coronary artery disease.
Differences in analytical methods may also have caused some of the
discrepancy. Therefore, we have joined a worldwide harmonization
initiative headed by Dr. Lütjohann.
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697Regarding the meta-analysis, it may be preferable to use indi-
vidual patient data compared with data extracted from various
publications with different models of adjustment. However, an
individual patient meta-analysis would not be expected to reveal a
different outcome because the studies included were consistent and
the overall results were highly signiﬁcant (p < 0.001) (1).
Cholesterol homeostasis in patients with chronic kidney disease
is indeed an interesting area of research because combination
therapy with simvastatin and the cholesterol absorption inhibitor
ezetimibe signiﬁcantly reduced cardiovascular events in these pa-
tients (5). It is still indeterminate, however, as to whether choles-
terol absorption predicts the effectiveness of statin use to prevent
cardiovascular complications in patients on chronic hemodialysis.
Finally, we have analyzed the associations of 12 single nucleotide
polymorphisms (rs11786580, rs6997473, rs4738687, rs1457042,
rs1457043, rs2162459, rs8192870, rs8192871, rs8192877, rs8192879,
rs3808607, rs3824260) within the CYP7A1 gene with circulating
cholestanol and the cholestanol/cholesterol ratio in both the LURIC
study and the YFS. None of these single nucleotide polymorphisms
were signiﬁcantly related to cholestanol or to the cholestanol ratio
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